ANVS · Annovis Bio, Inc.

Annovis Bio, Inc. (ANVS) reported significantly wider losses in Q1 2026, with operating income at -$18.0 million versus -$6.3 million in Q1 2025—a -186.7% year-over-year deterioration. This reflects the company's aggressive push into late-stage clinical development for its neurodegeneration therapies, where cash payments to fund studies have accelerated burn. Net income followed suit, reaching -$17.6 million from -$5.5 million (-218.0% YoY), with diluted EPS at -$0.63 compared to -$0.32 (-96.9% YoY). These results underscore the capital-intensive nature of biotech advancement, particularly as Phase 3 Alzheimer's Disease (AD) trial enrollment progresses.

Looking ahead, management believes existing cash will fund operating expenses and capital needs through Q4 2026, supporting ongoing Phase 3 AD enrollment. Screening is set to conclude May 15, 2026, with full enrollment two months later, marking key de-risking steps. However, they caution that losses are expected to increase further with clinical ramp-up and commercial readiness efforts. Operating plans remain fluid, and additional capital will be required to sustain momentum; absent sufficient funding or expense deferrals, scope reductions or operational cessation loom as risks.

This positions investors to monitor enrollment catalysts closely, as successful progression could validate Annovis' potential first-in-class approach to AD and Parkinson's Disease. Yet elevated burn and going-concern qualifiers highlight the high-stakes biotech dynamic, where trial outcomes will dictate financing needs and strategic viability.